Latest Breaking News On - Office of orphan drug products - Page 1 : comparemela.com

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoRichard waldronMecbotamab vedotinBruce mackleOffice of orphan drug productsMd anderson cancer centerExchange commissionDepartment of thoracicLifesci advisorsBioatla incAtla presented phaseTrial dataAmerica conferenceLung cancerConditionally active biologic

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the developm.

San diegoUnited statesRichard waldronMecbotamab vedotinBruce mackleLung cancer research foundationAndrew sabin foundationLungevity foundationJohns hopkins universityCancer research prevention institute of texasExchange commissionAmerican society of clinical oncologyOffice of orphan drug productsYork university school of medicineDepartment of thoracic head neck medical oncologyMd anderson cancer center

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesRichard waldronBruce mackleMecbotamab vedotinOzuriftamab vedotinExchange commissionBioatla incLifesci advisorsOffice of orphan drug productsStage programConditionally active biologicChief executive officerPleomorphic sarcomaCell carcinomaT cell engager clinical stage

Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia

Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNorthjuha karttunenphoneJo turnerphoneJames steelphoneContactlifesci advisorsdaniel ferrymanagingNomadsandy jamiesonPeel huntCairn financial advisersFaron pharmaceuticals oyMedia contactfaron pharmaceuticalsjenniferc smith parkerhead of communicationsOffice of orphan drug productsDrug administrationFaron pharmaceuticals ltdFirst northOrphan drug designationOrphan drug products

FDA Orphan Drug Designation for Bexmarilimab

Faron Pharmaceuticals Ltd. Inside Information: Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia ODD further strengthens bexmarilimab program.

United statesChristopher goldenJenniferc smith parkerJuha karttunenJo turnerSandy jamiesonPeel huntDrug administrationFaron pharmaceuticals ltdCompany announcementHead of communicationsCairn financial advisersOffice of orphan drug productsFaron pharmaceuticalsFaron receivesDrug designation